{"title":"Impact of Treatment Interruption on the Effectiveness of Interleukin (IL)-17A Inhibitors in Plaque Psoriasis: A Retrospective Analysis.","authors":"Jin Jiang, Meihua Zhang, Mi Li","doi":"10.2147/IJGM.S515389","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Plaque psoriasis is a chronic, recurrent, immune-mediated inflammatory skin disease. This study aimed to investigate effectiveness of interleukin (IL)-17A inhibitor treatment and effectiveness after treatment interruption in plaque psoriasis patients and analyze the related factors.</p><p><strong>Methods: </strong>This study retrospectively collected clinical characteristics and related treatment status of plaque psoriasis patients treated with IL-17A inhibitors, and evaluated the treatment effectiveness, reasons for treatment interruption, effectiveness after treatment interruption, and risk factors affecting treatment effectiveness.</p><p><strong>Results: </strong>This study ultimately included 106 patients with plaque psoriasis, including 61 males (57.55%) and 45 females (42.45%), aged 41.0 (31.0-54.0) years and with a disease duration of 12.0 (8.0-20.0) months. Among them, 71 cases (67%) achieved PASI90 after receiving IL-17A inhibitor treatment, and 35 cases (33.02%) achieved PASI75. A total of 50 patients (50/106, 47.17%) interrupted treatment, 23 patients (23/50, 46%) maintained a therapeutic effect of PASI90 or above, and 27 patients (27/50, 54%) had a therapeutic effect lower than PASI75, with median time of treatment interruption of 1.0 (1.0-3.5) months. Univariate analysis findings showed that duration of IL-17A inhibitor treatment interruption and reasons for interruption had significant statistical significance on treatment effectiveness (all P<0.05). In multivariate analysis, treatment interruption (OR=7.154, 95% CI: 2.528-20.24) and reasons such as stress/anxiety (OR: 14.889, 95% CI: 1.160-23.480) were risk factors affecting treatment effectiveness.</p><p><strong>Conclusion: </strong>Interleukin (IL)-17A inhibitor treatment interruption plays critical effects on the treatment of plaque psoriasis. Early and long-term adherence to IL-17A inhibitor treatment can control the course of the disease and improve the long-term health of psoriasis patients.</p>","PeriodicalId":14131,"journal":{"name":"International Journal of General Medicine","volume":"18 ","pages":"1681-1690"},"PeriodicalIF":2.0000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955164/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of General Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJGM.S515389","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Plaque psoriasis is a chronic, recurrent, immune-mediated inflammatory skin disease. This study aimed to investigate effectiveness of interleukin (IL)-17A inhibitor treatment and effectiveness after treatment interruption in plaque psoriasis patients and analyze the related factors.
Methods: This study retrospectively collected clinical characteristics and related treatment status of plaque psoriasis patients treated with IL-17A inhibitors, and evaluated the treatment effectiveness, reasons for treatment interruption, effectiveness after treatment interruption, and risk factors affecting treatment effectiveness.
Results: This study ultimately included 106 patients with plaque psoriasis, including 61 males (57.55%) and 45 females (42.45%), aged 41.0 (31.0-54.0) years and with a disease duration of 12.0 (8.0-20.0) months. Among them, 71 cases (67%) achieved PASI90 after receiving IL-17A inhibitor treatment, and 35 cases (33.02%) achieved PASI75. A total of 50 patients (50/106, 47.17%) interrupted treatment, 23 patients (23/50, 46%) maintained a therapeutic effect of PASI90 or above, and 27 patients (27/50, 54%) had a therapeutic effect lower than PASI75, with median time of treatment interruption of 1.0 (1.0-3.5) months. Univariate analysis findings showed that duration of IL-17A inhibitor treatment interruption and reasons for interruption had significant statistical significance on treatment effectiveness (all P<0.05). In multivariate analysis, treatment interruption (OR=7.154, 95% CI: 2.528-20.24) and reasons such as stress/anxiety (OR: 14.889, 95% CI: 1.160-23.480) were risk factors affecting treatment effectiveness.
Conclusion: Interleukin (IL)-17A inhibitor treatment interruption plays critical effects on the treatment of plaque psoriasis. Early and long-term adherence to IL-17A inhibitor treatment can control the course of the disease and improve the long-term health of psoriasis patients.
期刊介绍：
The International Journal of General Medicine is an international, peer-reviewed, open access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas.
A key focus of the journal is the elucidation of disease processes and management protocols resulting in improved outcomes for the patient. Patient perspectives such as satisfaction, quality of life, health literacy and communication and their role in developing new healthcare programs and optimizing clinical outcomes are major areas of interest for the journal.
As of 1st April 2019, the International Journal of General Medicine will no longer consider meta-analyses for publication.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
